NCT04556266 2025-05-13A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 MalignanciesMemorial Sloan Kettering Cancer CenterPhase 1 Withdrawn